These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29885546)

  • 1. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series.
    Kone-Paut I; Cimaz R; Herberg J; Bates O; Carbasse A; Saulnier JP; Maggio MC; Anton J; Piram M
    Autoimmun Rev; 2018 Aug; 17(8):768-774. PubMed ID: 29885546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
    Tremoulet AH; Jain S; Kim S; Newburger J; Arditi M; Franco A; Best B; Burns JC
    Contemp Clin Trials; 2016 May; 48():70-5. PubMed ID: 27080929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
    Koné-Paut I; Tellier S; Belot A; Brochard K; Guitton C; Marie I; Meinzer U; Cherqaoui B; Galeotti C; Boukhedouni N; Agostini H; Arditi M; Lambert V; Piedvache C
    Arthritis Rheumatol; 2021 Jan; 73(1):151-161. PubMed ID: 32779863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A child with resistant Kawasaki disease successfully treated with anakinra: a case report.
    Sánchez-Manubens J; Gelman A; Franch N; Teodoro S; Palacios JR; Rudi N; Rivera J; Antón J
    BMC Pediatr; 2017 Apr; 17(1):102. PubMed ID: 28390409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anakinra And Etanercept Combination Treatment in a Child With Severe, Nonresponsive Kawasaki Disease.
    Walser M; Hermann M; Hufnagel M; Haas NA; Fischer M; Dalla-Pozza R; Jakob A
    Pediatr Infect Dis J; 2020 Oct; 39(10):e310-e313. PubMed ID: 32618930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.
    Yang J; Jain S; Capparelli EV; Best BM; Son MB; Baker A; Newburger JW; Franco A; Printz BF; He F; Shimizu C; Hoshino S; Bainto E; Moreno E; Pancheri J; Burns JC; Tremoulet AH
    J Pediatr; 2022 Apr; 243():173-180.e8. PubMed ID: 34953816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroid treatment of refractory Kawasaki disease.
    Lang BA; Yeung RS; Oen KG; Malleson PN; Huber AM; Riley M; Ebbeson R; Ramsey SE; Laxer RM; Silverman ED; McCrindle BW; Ratnapalan S; Feldman BM
    J Rheumatol; 2006 Apr; 33(4):803-9. PubMed ID: 16583481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis.
    Gorelik M; Lee Y; Abe M; Andrews T; Davis L; Patterson J; Chen S; Crother TR; Aune GJ; Noval Rivas M; Arditi M
    Clin Exp Immunol; 2019 Oct; 198(1):101-110. PubMed ID: 31099056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm.
    Guillaume MP; Reumaux H; Dubos F
    Cardiol Young; 2018 May; 28(5):739-742. PubMed ID: 29455693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kawasaki disease in Sicily: clinical description and markers of disease severity.
    Maggio MC; Corsello G; Prinzi E; Cimaz R
    Ital J Pediatr; 2016 Nov; 42(1):92. PubMed ID: 27806720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial.
    Kessel C; Koné-Paut I; Tellier S; Belot A; Masjosthusmann K; Wittkowski H; Fuehner S; Rossi-Semerano L; Dusser P; Marie I; Boukhedouni N; Agostini H; Piedvache C; Foell D
    J Clin Immunol; 2022 Aug; 42(6):1330-1341. PubMed ID: 35699824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review.
    Ferrara G; Giani T; Caparello MC; Farella C; Gamalero L; Cimaz R
    Paediatr Drugs; 2020 Dec; 22(6):645-652. PubMed ID: 32885390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kawasaki disease: abnormal initial echocardiogram is associated with resistance to IV Ig and development of coronary artery lesions.
    Chbeir D; Gaschignard J; Bonnefoy R; Beyler C; Melki I; Faye A; Meinzer U
    Pediatr Rheumatol Online J; 2018 Jul; 16(1):48. PubMed ID: 30021610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis.
    Soni PR; Noval Rivas M; Arditi M
    Curr Rheumatol Rep; 2020 Feb; 22(2):6. PubMed ID: 32020498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.
    Lind-Holst M; Hartling UB; Christensen AE
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31383678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report.
    Shafferman A; Birmingham JD; Cron RQ
    Pediatr Rheumatol Online J; 2014; 12():26. PubMed ID: 25045337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of IL-6 in the LCWE Mouse Model of Kawasaki Disease Inhibits Acute Phase Reactant Serum Amyloid A but Fails to Attenuate Vasculitis.
    Porritt RA; Chase Huizar C; Dick EJ; Kumar S; Escalona R; Gomez AC; Marek-Iannucci S; Noval Rivas M; Patterson J; Forsthuber TG; Arditi M; Gorelik M
    Front Immunol; 2021; 12():630196. PubMed ID: 33897686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.